Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT04459611

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Condition or Disease	Intervention/Treatment	Phase
Non-small Cell Lung Cancer	Biological: sintilimab Drug: pemetrexed Drug: Carboplatin Drug: albumin-bound paclitaxel	Phase 2

Detailed Description

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. In this trial, eligible subjects will be randomly assigned to arm A and arm B (1:1). Subjects in arm A will receive 2 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy and arm B will receive 3 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy, followed by surgery within the 4th week after the last dose of sintilimab. After operation, subjects in arm A will receive 2 cycles of adjuvant chemotherapy and arm B will receive 1 cycle of adjuvant chemotherapy, followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients. The primary purpose is MPR rate of neoadjuvant chemotherapy of resectable NSCLC with different cycles of sintilimab combined with platinum-based chemotherapy, which is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.

Study Design

Study Type:

Interventional

Actual Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）：A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial

Actual Study Start Date :

Jul 1, 2020

Actual Primary Completion Date :

Nov 1, 2021

Anticipated Study Completion Date :

Jul 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy) Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.	Biological: sintilimab 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1. Other Names: IBI308 PD-1 antibody Drug: pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Drug: Carboplatin AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1. Drug: albumin-bound paclitaxel 260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
Experimental: sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy) Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.	Biological: sintilimab 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1. Other Names: IBI308 PD-1 antibody Drug: pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Drug: Carboplatin AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1. Drug: albumin-bound paclitaxel 260 mg/m^2 by IV infusion Q3W, given on cycle day 1.

Arm

Intervention/Treatment

Experimental: sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)

Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.

Biological: sintilimab

200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Other Names:

IBI308

PD-1 antibody

Drug: pemetrexed

500 mg/m^2 by IV infusion Q3W, given on cycle day 1.

Drug: Carboplatin

AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Drug: albumin-bound paclitaxel

260 mg/m^2 by IV infusion Q3W, given on cycle day 1.

Experimental: sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)

Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.

Biological: sintilimab

200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Other Names:

IBI308

PD-1 antibody

Drug: pemetrexed

500 mg/m^2 by IV infusion Q3W, given on cycle day 1.

Drug: Carboplatin

AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Drug: albumin-bound paclitaxel

260 mg/m^2 by IV infusion Q3W, given on cycle day 1.

Outcome Measures

Primary Outcome Measures

Major pathological response rate (MPR) [At time of surgery]
MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.

Secondary Outcome Measures

Pathology complete response rate(pCR) [At time of surgery]
pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens.
Objective response rate (ORR) [prior to surgery]
ORR is defined as the percentage of participants having a complete response or a partial response, measured by RECIST 1.1.
2 years disease-free survival rate (DFS) [2 years postoperatively]
2 years DFS rate is defined as the percentage of participants having no recurrence, distant metastasis or death within 2 years after operation.
2 years overall survival rate (OS) [2 years postoperatively]
2 years OS rate is defined as the percentage of participants having no death of any cause within 2 years after operation.The Kaplan-Meier estimator will be used to estimate median OS and its 95%CI and the survival curve.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Sign the informed consent form before starting any trial related procedure.
18-75 years old, male or female.
Non-small cell lung cancer confirmed by cytology or histology.
There must be at least one evaluable focus judged according to recist1.1 standard.
Evaluation by the researchers to confirm resectable stage cⅠb-Ⅲa NSCLC patients without any treatment before.
ECOG PS 0-1.
Life expectancy > 6 months.
Adequate organ function and it should meet the following criteria:

No use of Granulocyte colony stimulating factor within 14 days, absolute neutrophils count(ANC)≥1.5x109/L, platelets count(PLT)>9g/dL, hemoglobin(HB)≥100×109/L;
Total bilirubin(TBIL)≤1.5ULN, ALT、AST≤ 2.5 ULN, serum creatinine(sCr)≤1.5ULN;
good blood coagulation: INR≤1.5 or PT≤1.5 ULN;
normal thyroid function: TSH within normal institutional limits;

Women of childbearing age must undergo a serological pregnancy test within 3 days before the first dose(cycle 1 day 1) with negative results. If the result of urine pregnancy test cannot be confirmed as negative, blood pregnancy test is required.

Exclusion Criteria:

Malignancies within 5 years prior to the first dose(excluding radical skin basal cell carcinoma, skin squamous cell carcinoma and / or radical resection of carcinoma in situ).
Currently participating in the intervention clinical treatment, or receiving other drugs or research instruments within 4 weeks before the first dose.
Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or drugs for another stimulation or synergistic inhibition of T cell receptor (e.g. CTLA-4, OX-40, CD137).
Active autoimmune diseases requiring systemic treatment (e.g. using disease improving drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in physiological doses for adrenal or pituitary insufficiency) are not considered systemic treatment.
Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray, inhalation or other routes) or any other form of immunosuppressive therapy is in progress within 7 days before the first dose.

Note: it is allowed to use physiological dose of glucocorticoid (Prednisone≤10 mg/d or equivalent drug).

Received allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
Allergic to study drug(sintilimab, pemetrexed, carboplatin, albumin-bound paclitaxel) components excipients.
Not fully recovered from toxicity and/or complications caused by any intervention before treatment (≤level 1 or reach baseline, excluding fatigue or hair loss).
Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive).
Untreated active Hepatitis B (defined as HBsAg positive and HBV-DNA copies>ULN).
Active Hepatitis C (HCV antibody positive and HCV-RNA level higher than the detection limit).
Inoculate the live vaccine within 30 days before the first dose (cycle 1 day 1).

Note: it is allowed to receive the injection inactivated virus vaccine for seasonal influenza within 30 days before the first dose; however, it is not allowed to accept the live attenuated influenza vaccine for intranasal medication.

Pregnant or lactating women.
There are any serious or uncontrollable systemic diseases, such as:

Resting ECG has significant abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control,such as complete left bundle branch block, heart block above degree Ⅱ, ventricular arrhythmia or atrial fibrillation;
Unstable angina, congestive heart failure, chronic heart failure with NYHA grade ≥ 2;
Within 6 months before inclusion, there were any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack etc;
History of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose,or having currently clinical active interstitial lung diseases;
Active pulmonary tuberculosis;
Active or uncontrolled infections requiring systemic treatment;
Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
poorly controlled diabetes (Fasting blood glucose (FBG)>10mmol/L);
Urine routine test indicates that urine protein≥++, and confirmed that 24 hours proteinuria>1.0 g;
Patients with mental disorders who are unable to cooperate with the treatment;

There are medical history, disease, treatment or laboratory abnormal results that may interfere with the test results, prevent the subjects from participating in the whole process of the study, or the researchers think that participating in the study is not in the best interests of the subjects or there are other potential risks that the subjects are not suitable for the study.